Coherus Oncology Inc. announced six-year overall survival follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) in combination with chemotherapy for the first-line treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The study found that patients receiving LOQTORZI plus gemcitabine and cisplatin had a median overall survival of 64.8 months, compared to 33.7 months for chemotherapy alone, representing a 38% reduction in the risk of death (HR 0.62; 95% CI, 0.45-0.85). These long-term results reinforce LOQTORZI's role in combination therapy for RM-NPC. The findings were presented at ESMO Asia 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598270-en) on December 08, 2025, and is solely responsible for the information contained therein.